Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
GISSI trial showed that there is no benefit by giving heparin for preventing coronary reocclusion after thrombolysis with streptokinase. Heparin may be given to prevent mural thrombus formation in large infarctions. It may be considered in those with heart failure or atrial fibrillation to prevent thrombo-embolic complications.
